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2. Coronavirus update 
The Drug Harms Assessment and Response Team (DHART) is monitoring the 
impact of coronavirus (COVID-19) on drug markets and drug harm through a range 
of indicators. It is also collecting intelligence via various networks. Early indications 
suggest that: 
 
• overall national drug supply seems to have been fairly resilient 
• at a local level, there have been reported fluctuations in price, purity and 
availability 
• there have been reports of increased use of and harm linked to 
benzodiazepines and pregabalin
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• there may have been fewer presentations to emergency departments with 
acute drug toxicity 
• there is not currently evidence suggesting widespread substitution of heroin 
with fentanyl 
 
You should be aware that: 
 
1. Opioid substitute treatment (OST) practice has changed, supported by Public 
Health England (PHE) guidance, in response to the risk of COVID-19 
transmission. As a result, there has been less use of supervised consumption 
which increases the risk of medicines being diverted or not used as 
prescribed. 
2. Use of drugs such as opioids, benzodiazepines, gabapentinoids and alcohol 
can exacerbate breathing impairment from COVID-19. 
 
Public Health Scotland has issued harm reduction advice and information about 
drug use during COVID-19. 
 
3. Stimulants 
3.1 MDMA/ecstasy 
 
Key clinical messages 
MDMA remains widely available. Reported short-term harm can include psychiatric 
(anxiety, confusion and psychosis) and physical (liver, kidney and heart problems) 
symptoms. Other substances are sometimes sold as MDMA/ecstasy such as n-
ethyl-pentylone, a synthetic cathinone. 
 
Latest evidence 
Harm associated with MDMA use has been increasing among younger people. 
Deaths registered involving MDMA in England and Wales increased from 56 in 2017 
to 92 in 2018. The increase in deaths was primarily seen in the under 30s. Of those 
presenting to drug treatment in England, Wales and Scotland in 2018, one-quarter 
were aged under 15, with three-quarters aged under 20. 
 
3.2 Synthetic cathinones 
Synthetic cathinones include mephedrone, alpha-PVP, n-ethyl-pentylone and MDPHP. 
 
Key clinical messages 
Use of synthetic cathinones among the general population has decreased over the 
past decade. 
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Clinical management should follow existing stimulant protocols. 
 
Latest evidence 
The number of seizures of synthetic cathinones in England and Wales may have 
stabilised having previously fallen since 2018. 
 
There were 16 deaths registered involving synthetic cathinones in England and 
Wales in 2018. 
 
In January 2019, 3 people were hospitalised in Bury, Greater Manchester, after 
taking ‘UPS’ pills that contained high levels of alpha-PVP. Symptoms lasted 20 
hours, including agitation and psychosis. The availability of these pills appears to 
have been localised and contained. 
 
3.3 Cocaine (including crack cocaine) 
Key clinical messages 
Prevalence of cocaine use (including crack) appears to be increasing across the 
UK. 
 
There is increasing evidence that co-ingestion of cocaine and sildenafil (including 
Viagra) increases the risk of cardiac harms. You should consider asking cocaine 
users about sildenafil use, especially if there is pre-existing cardiovascular disease 
including a history of aortic dissection. 
 
Latest evidence 
Deaths involving cocaine (powder or crack) registered in England and Wales, 
Scotland and Northern Ireland in 2018 all reached the highest levels on record. 
 
Cocaine (powder and crack) purity and availability have been rising for several 
years and are currently high by historical standards. As well as more crack being 
taken by heroin users, there are signs of newer crack users who are not using 
heroin. 
 
The problem drug using population in Glasgow is increasingly injecting powder 
cocaine, and this was linked to a rise in HIV transmission. 
 
4. Sedatives and dissociatives 
4.1 Benzodiazepines 
Benzodiazepines and their analogues include diazepam (Valium), alprazolam 
(Xanax), etizolam, diclazepam and flualprazolam. 
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There is increased availability and use of illicitly manufactured ‘street’ 
benzodiazepines and their analogues, including alprazolam, etizolam, flualprazolam 
and temazepam. These substances are often sold as diazepam (Valium) or 
alprazolam (Xanax). 
 
Newer street benzodiazepines may not be detected in regular drug screens. The 
strength and toxicity of new benzodiazepines and their analogues can be 
unpredictable and often more potent than diazepam. 
 
Benzodiazepine use is particularly prevalent in Scotland and Northern Ireland. 
Street benzodiazepines, particularly etizolam, are often used by people who use 
opioids such as heroin in Scotland. 
 
In England, Xanax appears to be mainly used by young people, often with alcohol, 
and sometimes with other illicit drugs. However, etizolam is increasingly being 
identified in England and Wales, and may be sold as Xanax. 
 
Latest evidence 
Reports of benzodiazepine-related harm in England appear to have been increasing 
in recent years notably in the North East and North West. 
 
PHE issued a national alert in July 2020 containing advice on the availability and 
harm from illicit drugs sold as benzodiazepines, particularly when used with alcohol 
and drugs which have a respiratory depressant effect (including gabapentinoids and 
opioids). 
 
There is significant evidence from toxicology results of illicit tablets being sold as 
diazepam, temazepam and alprazolam linked to recent hospitalisations and deaths, 
and from police seizures, that some illicit drugs sold as benzodiazepines are 
causing harm. This includes tablets known as or marked with ‘DAN 5620’ (on one 
side) and ‘10’ (on the other), ‘T-20’, ‘TEM 20’, ‘Bensedin’ and ‘MSJ’ which may 
contain dangerously potent benzodiazepines or their analogues such as 
flubromazolam, flualprazolam and etizolam. Most of the tablets causing concern are 
blue (but they come in various colours) and these may stain people’s mouths. 
 
If you are in contact with people who use drugs, you should be alert to the increased 
possibility of overdose from illicit drugs sold as benzodiazepines, so you can raise 
awareness, be able to recognise possible symptoms of overdose and respond 
appropriately. The alert provides information and advises on the appropriate actions 
to take, including information to share with people who use drugs or are at risk of 
taking these drugs. 
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Street benzodiazepines were involved in 675 of the 1,187 drug-related deaths 
registered in Scotland in 2018. Etizolam was involved in 548 of these cases, most of 
which also involved opioids. 
 
Flualprazolam is increasingly being identified in the UK market and is reported to 
have a higher potency than alprazolam. Only 20% of samples purchased as 
alprazolam submitted to the Welsh Emerging Drugs and Identification of Novel 
Substances (WEDINOS) project so far in April to June 2020 contained alprazolam, 
with 25% containing flualprazolam. Also, 60% of supposed diazepam samples 
contained diazepam. 
 
Etizolam, diazepam and alprazolam were the most commonly identified 
benzodiazepines in seizures data from January to March 2020 in England and 
Wales. 
 
Etizolam and flualprazolam will become subject to international control under the 
United Nations (UN) Convention on Psychotropic Substances 1971 in November 
2020. 
 
4.2 Ketamine 
Key clinical messages 
Ketamine use appears to be increasing. You should ask patients reporting ketamine 
use about urological symptoms of ‘ketamine bladder’, including polyuria, dysuria and 
haematuria. 
 
Latest evidence 
There have been recent increases in ketamine-related police seizures, 
presentations to treatment, and prevalence of use in the last year among those 
aged 16 to 24. 
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4.3 Nitrous oxide (N2O) 
Key clinical messages 
Heavy and repeated use of N2O has been associated with severe peripheral 
neuropathy and rarely sub-acute combined degeneration of the spinal cord. 
 
Latest evidence 
Reports link heavy use (up to 75 cannisters per day) to peripheral neuropathy. 
 
5. Opioids 
5.1 Synthetic opioids 
Synthetic opioids detected in global drug markets include fentanyls, U-type opioids, 
AH-7921 and MT-45. 
 
Key clinical messages 
Synthetic pharmaceutical and illicit opioid use continues to be reported. The most 
common is fentanyl which can either be diverted from medical sources or illicitly 
manufactured. Some synthetic opioids (such as carfentanil) are highly potent, 
although they are rarely seen in the UK at present. 
 
Synthetic opioids may be mixed with, or substituted for, heroin resulting in users 
unknowingly consuming them. They may also be substituted for other opioids in 
counterfeit medicines. 
 
The number of deaths attributed to synthetic opioids (including fentanyl) in the UK 
remains very low compared to heroin, although this may be underestimated due to 
inconsistent post-mortem toxicological screening. 
 
You should consider possible synthetic opioid intoxication if patients present with 
signs and symptoms of severe opioid intoxication. Toxicology to confirm the 
substance(s) involved will support intelligence gathering. 
 
Clinical management of intoxication should follow existing opioid intoxication 
protocols. 
 
You should continue to use naloxone for all suspected opioid overdoses. Multiple 
doses of naloxone, or naloxone infusion, may be needed in acute settings. These 
may be more likely to be needed if highly potent synthetic opioids have been used. 
 
Risk of fentanyl toxicity via dermal absorption is low. However, PHE has published 
guidance for clinicians to reduce the risk of contamination. 
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See the heroin entry below for information on concurrent use of opioids with 
pregabalin, gabapentin and benzodiazepines, and the related overdose risk. 
 
Latest evidence 
In England and Wales there were 75 deaths registered involving fentanyl, 31 deaths 
involving fentanyl analogues and 2 novel opioids in 2017. In 2018, 74 deaths 
registered involved fentanyl, 31 involved fentanyl analogues and 11 involved novel 
opioids. 
 
The number of deaths involving synthetic opioids has been rising since 2013 and 
may be under-reported due to difficulties with detection. Twelve fentanyl deaths 
were registered in Scotland in 2018. Fentanyls are involved in relatively few deaths 
compared with heroin due to low prevalence. 
 
Adulteration of opioids and other drugs with fentanyl and its analogues is an 
established and common practice among suppliers in North American drug markets 
where these substances kill more drug users than other opioids like heroin. This is 
not currently the case in the UK but there is a clear need for vigilance. 
 
5.2 Heroin 
You should continue to treat overdose from heroin and other opioids with naloxone. 
Pregabalin, gabapentin and benzodiazepines are widely consumed by drug users 
alongside opioids, and are increasingly implicated in overdose. 
 
Deaths related to heroin are at an all-time high in England and Wales, Scotland and 
Northern Ireland. The average purity of street-level heroin has been high in recent 
years. 
 
6. Synthetic cannabinoid receptor agonists 
(SCRAs) 
People who use SCRAs will often call them ‘spice’ or ‘mamba’. 
 
  
8 
Key clinical messages 
SCRA use is most prevalent in prisons across the UK. Use among the general 
population is now low. Homeless populations are still known to be using SCRAs, 
although prevalence is less well documented. 
 
SCRAs are a diverse group of chemicals sold in a range of strengths. All are 
agonists for the CB1 receptor; some SCRAs may also work at other receptors. The 
chemicals sold are frequently changing, so harms are difficult to predict. 
 
The harms from SCRAs are often very different to those seen with herbal cannabis. 
SCRA toxicity can be severe, requiring management in intensive care units, and 
may be fatal. 
 
SCRAs can be vaped. Experts advise against using illicit and unregulated vaping 
products or adding substances to vaping fluids. 
 
Latest evidence 
Increased ambulance callouts in an area of the North West in early June 2020 were 
linked to a new SCRA or more potent blend of SCRAs. Subsequent testing of 
samples from this incident, a further incident in late July and samples seized in the 
city centre have found MDMB-4en-PINACA, 5F-MDMB-PICA and a mix of SCRAs. 
A hospital in the West Midlands also confirmed that it has been increasingly 
identifying MDMB-4en-PINACA in toxicology. 
 
In 2018, SCRAs contributed to 60 deaths registered in England and Wales, more 
than double the 24 deaths in 2017. This is despite signs of decreased use of these 
substances compared to previous years. There were 2 deaths involving SCRAs in 
Scotland in the same year. 
 
5F-MDMB-PICA and 4F-MDMB-BINACA increased in circulation in 2019. There are 
claims that they are stronger than and have different effects to other SCRAs. 
Although there were few detections of it prior to late 2019, MDMB-4en-PINACA is 
now also common and causing concern. New SCRAs are still entering the market, 
although there have been fewer new detections of these substances across Europe 
than seen previously. 
 
5F-MDMB-PICA and 4F-MDMB-BINACA are now subject to international control 
under the UN Convention on Psychotropic Substances 1971. 
 
Vitamin E acetate, an additive in some unregulated vaping products, has been 
strongly linked to cases of e-cigarette or vaping product use associated lung injury 
(EVALI) that has caused hospitalisations and deaths in the US. While the US 
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outbreak appeared to relate mainly to products containing THC, the risk of other 
unregulated vaping products causing EVALI cannot be discounted. 
 
7. Other substances 
7.1 Gabapentinoids 
Gabapentinoids include gabapentin (Neurontin) and pregabalin (Lyrica). 
 
Key clinical messages 
Prescriptions for pregabalin and gabapentin, together called gabapentinoids, are 
increasing. Gabapentinoids are licensed for the treatment of epilepsy, neuropathic 
pain and, in the case of pregabalin, generalised anxiety disorder. 
 
Gabapentinoids may be misused to increase the effects of opioids. They can lower 
opioid tolerance and induce respiratory depression at high doses. Opioids are often 
present in deaths involving gabapentinoids. 
 
Latest evidence 
Registered deaths in England and Wales involving gabapentinoids have been 
increasing. Between 2017 and 2018, deaths increased for gabapentin from 60 to 93 
and for pregabalin from 136 to 187. 
 
In Scotland, gabapentin- and pregabalin-related deaths rose from 142 to 194 and 
from 120 to 211 respectively over the same period. 
 
There were 54 deaths involving pregabalin in Northern Ireland registered in 2018, 
an increase from 9 in 2016. 
 
There are reports of increasing use and harm associated with gabapentinoids 
particularly pregabalin. 
 
7.2 2,4-Dinitrophenol (DNP) 
Key clinical messages 
DNP is a toxic chemical which has fat-burning properties and is sometimes used by 
body builders or by others seeking weight reduction. DNP interferes with cellular 
metabolism and prevents energy being stored as fat; instead the energy is released 
as heat. These effects are toxic to the cells of organs such as muscle, kidney and 
brain. Toxic effects are more common with higher doses. 
 
There is a myth that if DNP is used in small amounts, users will be safe. Although 
toxicity is common after overdose, severe and even fatal adverse effects have 
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occurred when the drug has been taken in the doses recommended on websites or 
by suppliers. 
 
If DNP toxicity is suggested, urgent referral to hospital is indicated. If you are 
dealing with individuals suspected of consuming DNP, you should seek advice on 
clinical management from the National Poisons Information Service (NPIS) by 
referring to TOXBASE. You can ring the NPIS on 0344 892 0111. 
 
You should also inform patients of the dangers and tell them to stop use 
immediately. All patients with features suggesting toxicity should be referred to 
hospital immediately for assessment and observation, and all symptomatic cases 
should be discussed with the NPIS by phone. 
 
Latest evidence 
From 2007 until the end of July 2020, there have been 137 separate episodes of 
systemic DNP exposure discussed with the NPIS. Of these, 25 (18%) are known to 
have died. During 2019, the NPIS recorded 14 cases of DNP toxicity and 4 deaths, 
both slight decreases from 2018 (20 cases, of which 6 were fatal). 
 
8. General clinical advice and updates 
The chemical makeup of new psychoactive substances (NPS) varies widely so you 
should treat acute presentations based on the symptoms at clinical presentation. 
 
NPIS’s TOXBASE has a symptom search function, which is useful if you do not 
know which drug was taken. Always ask about the use of other drugs and alcohol.  
 
Poly-substance use is common and may influence clinical presentation. If the actual 
substance taken is not known, consider treating according to broad psychoactive 
effect (for example sedatives and dissociatives, stimulants, hallucinogens or 
cannabinoids). 
 
Project NEPTUNE provides guidance on the clinical management of acute and 
chronic harms of club drugs and NPS and free e-learning modules. 
 
Drug misuse and dependence: UK guidelines on clinical management contains 
some information on the clinical management of people seeking treatment for NPS 
use. 
 
PHE has published guidance on NPS use for substance misuse commissioners and 
prison staff. 
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Manchester Health and Care Commissioning has produced a Spice information 
sheet, which provides information on its chemical make-up, effects and treatment. 
 
PHE has published evidence-based recommendations to protect first responders 
from exposure to fentanyl. 
 
9. Recent statistics and other data sources 
The Crime Survey for England and Wales 2018 to 2019 examines the extent and 
trends in illicit drug use among a sample of 16 to 59 year old residents in 
households in England and Wales. 
 
Annual statistics on alcohol and drug misuse treatment from PHE’s National Drug 
Treatment Monitoring System, includes reports on: 
 
• adults 
• young people 
• prisons and secure settings 
 
Smoking, drinking and drug use among young people in England in 2018. 
 
Scottish Schools Adolescent Lifestyle and Substance Use Survey 2018. 
 
Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among 
people who inject drugs (PWID) in 2018. 
 
The Office for National Statistics report on Deaths related to drug poisoning in 
England and Wales: 2018 registrations. 
 
The National Records of Scotland report on Drug-related deaths in Scotland in 
2018. 
 
The European Monitoring Centre for Drugs and Drug Addiction’s European Drug 
Report 2019. 
 
In 2020, the Advisory Council on the Misuse of Drugs published Misuse of fentanyl 
and fentanyl analogues and Novel benzodiazepines: a review of the evidence of use 
and harms of novel benzodiazepines. 
